Immunology Research Centre, Inflammation Research Group, School of Biochemistry and Immunology, Trinity College Dublin, Ireland.
Sci Transl Med. 2011 May 4;3(81):81ps17. doi: 10.1126/scitranslmed.3001902.
Atherosclerosis is the cause of morbiditiy for 70% of patients with type 2 diabetes. In both of these diseases, a protein complex known as the inflammasome is stimulated to activate interleukin-1β (IL-1β) and IL-18, which are pathogenic inflammatory cytokines. Triggers for the inflammasome are obesity-related factors, such as cholesterol crystals in atherosclerosis, or hyperglycemia, ceramides, and islet amyloid polypeptide in type 2 diabetes. Therapeutics that target IL-1β in clinical trials for type 2 diabetes might also decrease the incidence of atherosclerosis.
动脉粥样硬化是 70% 2 型糖尿病患者发病和致残的原因。在这两种疾病中，一种称为炎性小体的蛋白复合物被激活，从而激活白细胞介素-1β（IL-1β）和白细胞介素-18（IL-18），它们是致病性炎症细胞因子。炎性小体的触发因素是与肥胖相关的因素，如动脉粥样硬化中的胆固醇晶体，或 2 型糖尿病中的高血糖、神经酰胺和胰岛淀粉样多肽。在临床试验中针对 IL-1β 的治疗方法也可能降低动脉粥样硬化的发生率。
